Lung cancer immunotherapy era begins - HEALTYMON - healty exercise

Sunday, January 5, 2020

Lung cancer immunotherapy era begins

prof. Dr. Ahmet Bilici chemotherapy in the treatment of lung cancer in the last 15 years, as well as new treatments are developed, stating that, "today, targeted drugs and immunotherapy in the treatment of lung cancer patients it was a new and promising method," he said.

Medipol Mega University Hospital Medical Oncology Department Prof. Dr. Chemotherapy is not the only option to treat lung cancer. Prof. Dr. Bilici, lung cancer is the most common cause of cancer-related deaths in both men and women, stating that "in the world, both women and men are the second most common type of cancer. Only chemotherapy in the treatment of lung cancer for a long time and was used as the only treatment method is still being used. On the other hand, as with other types of cancer, especially advanced stage of lung cancer in the treatment of the disease in recent years, significant improvements have been noted and new treatments have entered into practice," he said.


In the last 15 years, Prof. Dr. Bilici made the following assessment:

"When deciding whether to treat lung cancer, it was enough to divide patients into only small-cell and non-small-cell. The patients were treated with similar chemotherapy, whichever of these two types was included. In other words, there was no differentiated, individual treatment approach. However, learning the molecular pathological and biological properties of lung cancer, especially in the last 15 years, has led to the research of new treatments. Primarily non-small cell lung cancer pathological subtypes and different biological characteristics of different, the differences of treatment we learned. After that, can play a role especially in the formation of lung cancer cells, 'mutation', which revealed some of the genetic changes in several genes. These genetic changes are then targeted at the person-specific or 'target-oriented' treatments called treatments were developed."


Prof. Dr. Bilici, target-oriented drugs have fewer side effects than chemotherapy, he said, shared the following information:

"The most important feature of targeted drugs is that the patient can destroy cancer cells by acting on a genetic mutation specific to lung cancer. This is why they can also be called person-specific or smart drugs. Another feature of these drugs, such as chemotherapy does not affect both normal and lung cancer cells. More lung cancer cells related to normal cells, more cancer cells through effects on the carrying of the mutation does not little or no harm. It is important for the patient, unlike chemotherapy, hair loss, nausea, vomiting, diarrhea, mouth sores, such as side effects that can negatively affect the patient's quality of life are not seen at all or are mild. In this way, the normal daily life of our lung cancer patient continues and the comforts of life can be maintained."


The success rate is also higher in targeted treatments. Dr. Bilici "chemotherapies, but 30 percent of the response to treatment such as the rate can get, 70 percent to 80 percent of the rate of targeted treatments can go up. Thus, the progression of the disease can be prevented for longer and the treatment success of our patients increases 2-3 times. However, individual-specific treatments are only being used in advanced-stage patients for the moment, " he said.

Prof. Dr. Bilici continued:

"In all of our patients with advanced-stage small-cell lung cancer, especially squamous-cell types, we want the necessary genetic testing as a standard in order to investigate compliance with such targeted therapies at the time of diagnosis. For the moment, EGFR, ALK, ROS-1, B-RAF tests are the genetic tests we want for targeted drugs. In fact, although there are many genetic mutations in non-small cell lung cancer, the rate of such mutations leading the treatment can be determined around 20 to 30 percent. If one of these is found, we can achieve more successful results by treating patients with appropriate drugs."


Prof. Dr. Another important development in lung cancer treatment is immunotherapies, Bilici said.:

"The understanding that in many tumours the immune system cells have a lack of recognition and destruction of cancer cells has led to the research of drugs to correct this disorder. For a similar purpose in lung cancer immunotherapy have been investigated, and recently it was demonstrated the effectiveness of three drugs for the treatment of advanced stage lung cancer. Immunotherapies have started a battle against the tumor by acting on T-lymphocytes in the patient's own immune system, correcting the disorder in recognizing and destroying the tumor in the immune system. These drugs were primarily used in advanced non-small cell lung cancer, with very positive results and started to be used all over the world. On the other hand, recently spread to the regional lymph nodes and spread to distant organs non-small cell lung cancer after chemotherapy and radiation therapy, so a more aggressive maintenance therapies maintenance and finally as trending-the efficacy of immunotherapy in metastatic stage of small cell lung cancer was shown. It has been shown to positively skew patient outcomes compared to standard chemotherapy. Thus, targeted drugs and immunotherapies are the newest and most promising treatments in the treatment of our lung cancer patients."

No comments:

Post a Comment